Blosozumab (LY2541546) is a humanized monoclonal antibody targeting sclerostin, promoting bone formation and inhibiting bone resorption, used in osteoporosis research. Blosozumab increases bone mass by neutralizing the negative effects of sclerostin on the Wnt signaling pathway.
Purity:
98.70%
CAS Number:
[1132758-87-2]
Target:
Wnt/beta-catenin
* VAT and and shipping costs not included. Errors and price changes excepted